Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet? - Wikidata - awgldk - TriplyDB

Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?

Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?

http://www.wikidata.org/entity/Q38666159

about

Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?

http://www.wikidata.org/entity/Q38666159

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?

@en

type

label

Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?

@en

prefLabel

Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?

@en

P1433

Q38666159-9EABD848-F06D-4F93-8B9E-5249A7E71FBC

P1476

Q38666159-68E7E3EB-5CA2-449E-9FF0-650F1120F82D

P2093

Q38666159-E7D68804-5BD4-480F-833E-EB510BD47A5F

P2860

Q38666159-0117D744-BBAD-467A-BD64-613418F43BAF

Q38666159-03D69FD9-5851-4EBE-8C88-B92DA526605A

Q38666159-04F1B0F5-8850-42C8-A3D5-B2C9D64C7CB4

Q38666159-06E5527A-CF6D-45BA-A924-1E287F7A9CEA

Q38666159-06EDA4FD-931E-489A-AB42-B9950949E6B8

Q38666159-0A847F19-30EB-466A-AEB6-56E5962EC590

Q38666159-0E46B21F-4A4A-4D63-8A4D-D6AEE0B83192

Q38666159-14034124-F86C-48CB-95DC-E26773C84E2D

Q38666159-18022234-C695-44F5-AB6E-AE2610458A92

Q38666159-18477DF0-9DBD-468E-AB15-61DD51A3297E

P304

Q38666159-7E1D176F-49AA-48E2-8BAA-D6F3E56B528B

P31

Q38666159-1431BDFF-A5DA-49B6-9DC2-41DFBC427930

P356

Q38666159-2C689521-09C6-4BC2-B93F-ED54A92BBE93

P407

Q38666159-8ACA315C-35C9-4DAA-A8E3-B6A9713577D4

P433

Q38666159-94E17BE3-8244-46AD-BD0C-E1A7B1155B62

P478

Q38666159-1B8E47A6-F0B7-442D-BC7D-5E5340171497

P50

Q38666159-B7D09F4C-7460-44D6-BE9E-10BF5EBCAD05

P577

Q38666159-FC3B62CF-A2D3-4D4B-AEB8-D6FD43992E8C

P698

Q38666159-E038A230-E1B2-4010-876E-C6634B20FC38

P356

P1433

Pharmacotherapy

P1476

Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?

@en

P2093

Hilary Ma

http://www.w3.org/2001/XMLSchema#string

P2860

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.

Implications of NRAS mutations in AML: a study of 2502 patients.

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML

P304

1052-1072

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PHAR.1977

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28654205

http://www.w3.org/2001/XMLSchema#string